Search by Drug Name or NDC
NDC 00007-3385-13 COREG 20 mg/1 Details
COREG 20 mg/1
COREG is a ORAL CAPSULE, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by GlaxoSmithKline LLC. The primary component is CARVEDILOL PHOSPHATE.
MedlinePlus Drug Summary
Carvedilol is used to treat heart failure (condition in which the heart cannot pump enough blood to all parts of the body) and high blood pressure. It also is used to treat people who have had a heart attack. Carvedilol is often used in combination with other medications. Carvedilol is in a class of medications called beta-blockers. It works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 00007-3385-13Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Carvedilol
Product Information
| NDC | 00007-3385 |
|---|---|
| Product ID | 0007-3385_d03bd95a-f9f1-4f4a-9ea5-bc972ad55761 |
| Associated GPIs | 33300007207020 |
| GCN Sequence Number | 061812 |
| GCN Sequence Number Description | carvedilol phosphate CPMP 24HR 20 MG ORAL |
| HIC3 | J7A |
| HIC3 Description | ALPHA/BETA-ADRENERGIC BLOCKING AGENTS |
| GCN | 97597 |
| HICL Sequence Number | 034245 |
| HICL Sequence Number Description | CARVEDILOL PHOSPHATE |
| Brand/Generic | Brand |
| Proprietary Name | COREG |
| Proprietary Name Suffix | CR |
| Non-Proprietary Name | carvedilol phosphate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 20 |
| Active Ingredient Units | mg/1 |
| Substance Name | CARVEDILOL PHOSPHATE |
| Labeler Name | GlaxoSmithKline LLC |
| Pharmaceutical Class | Adrenergic alpha-Antagonists [MoA], Adrenergic beta1-Antagonists [MoA], Adrenergic beta2-Antagonists [MoA], alpha-Adrenergic Blocker [EPC], beta-Adrenergic Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA022012 |
| Listing Certified Through | n/a |
Package
NDC 00007-3385-13 (00007338513)
| NDC Package Code | 0007-3385-13 |
|---|---|
| Billing NDC | 00007338513 |
| Package | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0007-3385-13) |
| Marketing Start Date | 2019-11-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |